Jubilant Pharmova Limited (BOM:530019)

Jubilant Pharmova Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	76,176	72,345	67,029	62,817	61,302	60,985
Revenue Growth (YoY)	10.09%	7.93%	6.71%	2.47%	0.52%	2.05%
Cost of Revenue	26,339	25,357	23,513	20,816	14,880	15,360
Gross Profit	49,837	46,988	43,516	42,001	46,422	45,625
Selling, General & Admin	24,532	23,431	22,873	22,151	20,739	19,440
Other Operating Expenses	12,684	11,837	11,593	12,011	13,621	11,509
Operating Expenses	41,110	38,954	38,285	38,252	38,023	34,183
Operating Income	8,727	8,034	5,231	3,749	8,398	11,443
Interest Expense	-1,881	-2,209	-2,564	-1,686	-1,382	-1,734
Interest & Investment Income	366	366	261	98	24.51	80.97
Earnings From Equity Investments	-6	-5	511	123	-99.83	112.52
Currency Exchange Gain (Loss)	6	6	-42	172	-464.53	-644.67
Other Non Operating Income (Expenses)	-137	2	-5	-83	14.45	-40.22
EBT Excluding Unusual Items	7,075	6,194	3,392	2,373	6,491	9,218
Gain (Loss) on Sale of Investments	17	17	2	-50	1.47	28.23
Gain (Loss) on Sale of Assets	-	-	-	-27	-33.7	-66.91
Asset Writedown	3,595	3,595	-1,689	-1,450	-153.83	-255.81
Other Unusual Items	-3,875	-	-	-568	-	-212.31
Pretax Income	6,812	9,806	1,705	278	6,304	8,711
Income Tax Expense	2,068	1,443	978	927	2,174	2,972
Earnings From Continuing Operations	4,744	8,363	727	-649	4,130	5,739
Earnings From Discontinued Operations	-	-	-	-	-	2,618
Net Income to Company	4,744	8,363	727	-649	4,130	8,356
Minority Interest in Earnings	33	31	44	39	9.2	2.58
Net Income	4,777	8,394	771	-610	4,139	8,359
Net Income to Common	4,777	8,394	771	-610	4,139	8,359
Net Income Growth	-19.46%	988.72%	-	-	-50.48%	-6.94%
Shares Outstanding (Basic)	158	158	159	159	159	159
Shares Outstanding (Diluted)	159	159	159	159	159	159
Shares Change (YoY)	-0.01%	0.01%	-0.18%	-0.02%	-0.06%	-0.01%
EPS (Basic)	30.15	52.98	4.86	-3.83	26.01	52.48
EPS (Diluted)	30.08	52.85	4.86	-3.83	26.00	52.48
EPS Growth	-19.42%	987.45%	-	-	-50.46%	-6.93%
Free Cash Flow	-995	-435	736	-1,538	2,376	12,568
Free Cash Flow Per Share	-6.26	-2.74	4.63	-9.66	14.92	78.91
Dividend Per Share	-	5.000	5.000	5.000	5.000	5.000
Gross Margin	65.42%	64.95%	64.92%	66.86%	75.73%	74.81%
Operating Margin	11.46%	11.11%	7.80%	5.97%	13.70%	18.76%
Profit Margin	6.27%	11.60%	1.15%	-0.97%	6.75%	13.71%
Free Cash Flow Margin	-1.31%	-0.60%	1.10%	-2.45%	3.88%	20.61%
EBITDA	11,378	10,477	7,933	6,463	10,663	14,676
EBITDA Margin	14.94%	14.48%	11.83%	10.29%	17.39%	24.07%
D&A For EBITDA	2,651	2,443	2,702	2,714	2,264	3,234
EBIT	8,727	8,034	5,231	3,749	8,398	11,443
EBIT Margin	11.46%	11.11%	7.80%	5.97%	13.70%	18.76%
Effective Tax Rate	30.36%	14.71%	57.36%	333.45%	34.49%	34.12%
Revenue as Reported	76,605	72,913	67,716	63,200	61,415	61,162
Advertising Expenses	-	687	664	413	259.84	161.77

Source: S&P Global Market Intelligence. Standard template. Financial Sources.